Top 22 medical and healthcare startups in Denmark
Mar 21, 2026
|
Like
16
1
Funding: $5.7B
Genmab is a biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer.
Genmab is a biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer.
2
Funding: $721.3M
Transmedics is a medical device company involved in the design and production of transplant devices.
Transmedics is a medical device company involved in the design and production of transplant devices.
3
Funding: $720.3M
Galecto develops galectin modulators for the treatment of severe diseases, including fibrosis and cancer. The company builds on more than 10 years of research into galectins and galectin modulators, which combined with a strong patent estate gives Galecto Biotech a unique platform.
Galecto develops galectin modulators for the treatment of severe diseases, including fibrosis and cancer. The company builds on more than 10 years of research into galectins and galectin modulators, which combined with a strong patent estate gives Galecto Biotech a unique platform.
4
Funding: $249.6M
ADCendo develops antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical needs. The company is developing two technologies: ADCE-T02, which combines an optimized monoclonal antibody targeting tissue factor (overexpressed in numerous solid tumor indications) with a next-generation linker and exatecan delivery technology, providing higher efficacy and improved tolerability. The second candidate is ADCE-D01 - a first-in-class ADC targeting uPARAP, an endocytic receptor overexpressed in a wide range of mesenchymal tumors, including soft tissue sarcomas, osteosarcoma, GISTs, mesothelioma and glioblastoma.
ADCendo develops antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical needs. The company is developing two technologies: ADCE-T02, which combines an optimized monoclonal antibody targeting tissue factor (overexpressed in numerous solid tumor indications) with a next-generation linker and exatecan delivery technology, providing higher efficacy and improved tolerability. The second candidate is ADCE-D01 - a first-in-class ADC targeting uPARAP, an endocytic receptor overexpressed in a wide range of mesenchymal tumors, including soft tissue sarcomas, osteosarcoma, GISTs, mesothelioma and glioblastoma.
5
Funding: $235M
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines.
6
Funding: $215.5M
Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.
Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.
7
Funding: $190M
Hemab is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.
Hemab is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.
8
Funding: $190M
Hemab is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.
Hemab is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.
9
Funding: €151M
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders. Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders. Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.
10
Funding: $103.4M
SNIPR Biome is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future.Precision killing of bacteria has the impact to revolutionise the management of untreatable and difficult-to-treat infections as well as complex diseases directly impacted by the human microbiota.
SNIPR Biome is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future.Precision killing of bacteria has the impact to revolutionise the management of untreatable and difficult-to-treat infections as well as complex diseases directly impacted by the human microbiota.
11
Funding: $93.3M
Corti is a machine learning company that helps emergency departments to detect critical illnesses like cardiac arrest in real-time.
Corti is a machine learning company that helps emergency departments to detect critical illnesses like cardiac arrest in real-time.
12
Funding: $90.6M
Antag Therapeutics provides therapeutic peptides for the treatment of dietary-related metabolic diseases like obesity.
Antag Therapeutics provides therapeutic peptides for the treatment of dietary-related metabolic diseases like obesity.
13
Funding: $77.9M
Muna develops transformative therapeutics to preserve brain function and enhance resilience to neurodegenerative diseases
Muna develops transformative therapeutics to preserve brain function and enhance resilience to neurodegenerative diseases
14
Funding: €52M
Lenus eHealth is a B2B technology and innovation firm providing cloud-based SaaS to a broad variety of health professionals.
Lenus eHealth is a B2B technology and innovation firm providing cloud-based SaaS to a broad variety of health professionals.
15
Funding: $52.3M
MedTrace provides 15O water for positron emission tomography (PET) imaging. The startup’s platform consists of an automated hardware system for producing, dosing, and injecting 15O water and analytical software for image processing.
MedTrace provides 15O water for positron emission tomography (PET) imaging. The startup’s platform consists of an automated hardware system for producing, dosing, and injecting 15O water and analytical software for image processing.
16
Funding: $43.5M
Liva’s digital coaching platform provides scalable lifestyle change, disease management & patient engagement for NHS England, AXA PPP & more
Liva’s digital coaching platform provides scalable lifestyle change, disease management & patient engagement for NHS England, AXA PPP & more
17
Funding: $38M
Dawn Health is a digital health company specializing in developing regulated software-as-a-medical-device and digital therapeutics, used in oncology and for multiple sclerosis and rare pediatric conditions, like growth disorders
Dawn Health is a digital health company specializing in developing regulated software-as-a-medical-device and digital therapeutics, used in oncology and for multiple sclerosis and rare pediatric conditions, like growth disorders
18
Funding: $12M
Nøie is customised skincare based on individual skin profiles, scientifically proven ingredients, and shared knowledge within a community united by similar issues. Our algorithms harness the power of the crowd to help the individual.
Nøie is customised skincare based on individual skin profiles, scientifically proven ingredients, and shared knowledge within a community united by similar issues. Our algorithms harness the power of the crowd to help the individual.
19
Funding: $6.5M
Motosumo is unlocking that potential using our background in professional sports analysis.
Motosumo is unlocking that potential using our background in professional sports analysis.
20
Funding: $5.2M
Radiobotics are developing stellar machine learning algorithms, supporting doctors in analysing medical images.
Radiobotics are developing stellar machine learning algorithms, supporting doctors in analysing medical images.
21
Sonohaler is a digital health company that empowers people with asthma live an active and healthy life.
22
Cystotech uses artificial intelligence to improve bladder cancer treatment. They develop applications for use during cystoscopy and focus on improving diagnostic efficiency and use less invasive treatment approaches. Cystotech's technology improves tumor grade assessment, allowing surgeons to perform resections to the correct depth during primary tumor resection. This will reduce the recurrence rate and, consequently, the number of surgical interventions.
★
See also:
